Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.244 EUR -2.4% Market Closed
Market Cap: 30.4m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SIGHT stock under the Base Case scenario is 0.238 EUR. Compared to the current market price of 0.244 EUR, Gensight Biologics SA is Overvalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SIGHT Relative Value
Base Case
0.238 EUR
Overvaluation 2%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

12.9
P/S
P/S
Price to Sales
12.9
vs History
98
vs Industry
29
Median 3Y
38.9
Median 5Y
59.1
Industry
7.3
Forward
8.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-10.9
Industry
21.6
Forward
-0.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
2
Median 3Y
-2.8
Median 5Y
-13.3
Industry
19.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
11
Median 3Y
-3.9
Median 5Y
-12.7
Industry
24.9
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
53
Median 3Y
-1.6
Median 5Y
-1.4
Industry
2.4
More Details
16.8
EV/S
EV/S
Enterprise Value to Sales
16.8
vs History
93
vs Industry
24
Median 3Y
39.3
Median 5Y
53
Industry
7.4
Forward
10.6
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2
Median 5Y
-10.6
Industry
3.9
Forward
-1.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-10.3
Industry
3.7
Forward
-1.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
2
Median 3Y
-3.1
Median 5Y
-13
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
3
Median 3Y
-3.1
Median 5Y
-13
Industry
3.2
More Details
12.1
EV/IC
EV/IC
Enterprise Value to IC
12.1
vs History
96
vs Industry
10
Median 3Y
39.1
Median 5Y
58.7
Industry
4.3
More Details

Multiples Across Competitors

SIGHT Competitors Multiples
Gensight Biologics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Gensight Biologics SA
PAR:SIGHT
30.4m EUR 12.9 -0.9 -1.1 -1.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 539 777.2 -173 668.1 -210 888.4 -208 482
US
Abbvie Inc
NYSE:ABBV
372.9B USD 6.6 88.1 17.2 25.9
US
Amgen Inc
NASDAQ:AMGN
167.8B USD 5 41.1 16.5 29.3
US
Gilead Sciences Inc
NASDAQ:GILD
138.8B USD 4.8 289.2 11.3 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.4B USD 11.7 -241.6 26.5 27.7
US
Epizyme Inc
F:EPE
94.1B EUR 1 928 -492 -535.7 -521.5
AU
CSL Ltd
ASX:CSL
121.1B AUD 5 27.7 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.8B USD 5.1 16.5 10.9 12.1
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.3 -55.3
NL
argenx SE
XBRU:ARGX
32B EUR 15.9 41.7 306.7 -2 259.2
P/S Multiple
Revenue Growth P/S to Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average P/S: 3 321 981
12.9
54%
0.2
FR
Pharnext SCA
OTC:PNEXF
36 539 777.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 928
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
15.9
37%
0.4
P/E Multiple
Earnings Growth PEG
FR
Gensight Biologics SA
PAR:SIGHT
Average P/E: 84
Negative Multiple: -0.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 668.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.1
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.1
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
289.2
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -492 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
NL
argenx SE
XBRU:ARGX
41.7
19%
2.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average EV/EBITDA: 58
Negative Multiple: -1.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 888.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.5
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
NL
argenx SE
XBRU:ARGX
306.7
168%
1.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Gensight Biologics SA
PAR:SIGHT
Average EV/EBIT: 21.8
Negative Multiple: -1.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 482 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.9
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 259.2 N/A N/A

See Also

Summary
SIGHT intrinsic value, competitors valuation, and company profile.
DCF Valuation
SIGHT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SIGHT stock valuation using valuation multiples.
Wall Street Estimates
SIGHT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SIGHT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 238,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.